Refractory Epidermolysis Bullosa Acquisita with Chronic Graft-versus-Host Disease Successfully Treated with Rituximab
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Rituximab in the Treatment of Epidermolysis Bullosa Acquisita: A Systematic Review.
Kianfar N, Dasdar S, Marashi A, Tavakolpour S, Mahmoudi H, Daneshpazhooh M J Clin Aesthet Dermatol. 2024; 17(7):24-36.
PMID: 39006807 PMC: 11238708.
References
1.
Izumi R, Fujimoto M, Yazawa N, Nakashima H, Asashima N, Watanabe R
. Bullous pemphigoid positive for anti-BP180 and anti-laminin 5 antibodies in a patient with graft-vs-host disease. J Am Acad Dermatol. 2007; 56(5 Suppl):S94-7.
DOI: 10.1016/j.jaad.2006.10.986.
View
2.
Hofmann S, Kopp G, Gall C, Bruckner-Tuderman L, Bertz H
. Basement membrane antibodies in sera of haematopoietic cell recipients are associated with graft-versus-host disease. J Eur Acad Dermatol Venereol. 2009; 24(5):587-94.
DOI: 10.1111/j.1468-3083.2009.03480.x.
View
3.
Kim J, Kim S
. Epidermolysis bullosa acquisita. J Eur Acad Dermatol Venereol. 2013; 27(10):1204-13.
DOI: 10.1111/jdv.12096.
View
4.
Solomon S, Sizemore C, Ridgeway M, Zhang X, Brown S, Holland H
. Safety and efficacy of rituximab-based first line treatment of chronic GVHD. Bone Marrow Transplant. 2018; 54(8):1218-1226.
DOI: 10.1038/s41409-018-0399-7.
View
5.
Kato K, Koike K, Kobayashi C, Iijima S, Hashimoto T, Tsuchida M
. Bullous pemphigoid after allogeneic hematopoietic stem cell transplantation. Pediatr Int. 2015; 57(3):480-3.
DOI: 10.1111/ped.12561.
View